About Marizyme
Redefining the Standard of Surgical Care
Marizyme, Inc. is a global medical technology company dedicated to transforming the landscape of cardiac care. We bridge the gap between advanced biotechnology and clinical practice by developing first-in-class vascular conduit solutions that address the most critical surgical challenges in coronary artery bypass graft (CABG) surgery.
Our core mission is to safeguard patient outcomes through the maintenance of vascular integrity, utilizing a proprietary platform designed to neutralize oxidative damage— a critical driver of vein graft ischemic reperfusion injury.
Clinical Innovation: Developer of DuraGraft - the first and only FDA-cleared vascular conduit solution that maintains the structural and functional integrity of saphenous vein grafts.
Fiscal Resilience: We want to provide hospital systems with a strategic tool to reduce the financial burden of repeat procedures and extended hospital stays.
Strategic Scale: With a patent portfolio spanning 30+ countries and national agreements with networks, we are built for long-term market leadership and sustainability.